Follow
Kayode Ogungbenro
Kayode Ogungbenro
Verified email at manchester.ac.uk
Title
Cited by
Cited by
Year
Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis
P Domingo, I Mur, GM Mateo, M del Mar Gutierrez, V Pomar, N de Benito, ...
Jama 326 (6), 499-518, 2021
4652021
Why has model‐informed precision dosing not yet become common clinical reality? Lessons from the past and a roadmap for the future
AS Darwich, K Ogungbenro, AA Vinks, JR Powell, JL Reny, N Marsousi, ...
Clinical Pharmacology & Therapeutics 101 (5), 646-656, 2017
2032017
Effect of convalescent plasma on organ support–free days in critically ill patients with COVID-19: a randomized clinical trial
H Abdelhady, M Abdelrazik, Z Abdi, D Abdo, A Abdulle, L Abel, ...
Jama 326 (17), 1690-1702, 2021
1872021
Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study
J Galea, K Ogungbenro, S Hulme, A Greenhalgh, L Aarons, S Scarth, ...
Journal of Cerebral Blood Flow & Metabolism 31 (2), 439-447, 2011
1262011
The population pharmacokinetics of R‐ and S‐warfarin: effect of genetic and clinical factors
S Lane, S Al‐Zubiedi, E Hatch, I Matthews, AL Jorgensen, P Deloukas, ...
British journal of clinical pharmacology 73 (1), 66-76, 2012
1102012
Reduction of inflammation after administration of interleukin-1 receptor antagonist following aneurysmal subarachnoid hemorrhage: results of the Subcutaneous Interleukin-1Ra in …
J Galea, K Ogungbenro, S Hulme, H Patel, S Scarth, M Hoadley, ...
Journal of neurosurgery 128 (2), 515-523, 2017
1052017
Model-informed precision dosing: background, requirements, validation, implementation, and forward trajectory of individualizing drug therapy
AS Darwich, TM Polasek, JK Aronson, K Ogungbenro, DFB Wright, ...
Annual review of pharmacology and toxicology 61, 225-245, 2021
972021
Methods and software tools for design evaluation in population pharmacokinetics–pharmacodynamics studies
J Nyberg, C Bazzoli, K Ogungbenro, A Aliev, S Leonov, S Duffull, ...
British journal of clinical pharmacology 79 (1), 6-17, 2015
922015
Capsaicin-evoked cough responses in asthmatic patients: evidence for airway neuronal dysfunction
I Satia, N Tsamandouras, K Holt, H Badri, M Woodhead, K Ogungbenro, ...
Journal of Allergy and Clinical Immunology 139 (3), 771-779. e10, 2017
912017
Optimal design of pharmacokinetic studies
L Aarons, K Ogungbenro
Basic & clinical pharmacology & toxicology 106 (3), 250-255, 2010
862010
Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial
S Florescu, D Stanciu, M Zaharia, A Kosa, D Codreanu, A Kidwai, ...
Jama 329 (1), 39-51, 2023
802023
Optimal design for multivariate response pharmacokinetic models
I Gueorguieva, L Aarons, K Ogungbenro, KM Jorga, T Rodgers, ...
Journal of Pharmacokinetics and Pharmacodynamics 33, 97-124, 2006
712006
Age related changes in fractional elimination pathways for drugs: assessing the impact of variable ontogeny on metabolic drug–drug interactions
F Salem, TN Johnson, ZE Barter, JS Leeder, A Rostami‐Hodjegan
The Journal of Clinical Pharmacology 53 (8), 857-865, 2013
662013
Gaining mechanistic insight into coproporphyrin I as endogenous biomarker for OATP1B‐mediated drug–drug interactions using population pharmacokinetic modeling and simulation
S Barnett, K Ogungbenro, K Ménochet, H Shen, Y Lai, WG Humphreys, ...
Clinical Pharmacology & Therapeutics 104 (3), 564-574, 2018
652018
Advanced methods for dose and regimen finding during drug development: summary of the EMA/EFPIA workshop on dose finding (London 4–5 December 2014)
FT Musuamba, E Manolis, N Holford, SYA Cheung, LE Friberg, ...
CPT: pharmacometrics & systems pharmacology 6 (7), 418-429, 2017
652017
A program for individual and population optimal design for univariate and multivariate response pharmacokinetic–pharmacodynamic models
I Gueorguieva, K Ogungbenro, G Graham, S Glatt, L Aarons
Computer methods and programs in biomedicine 86 (1), 51-61, 2007
632007
Dose rationalization of pembrolizumab and nivolumab using pharmacokinetic modeling and simulation and cost analysis
K Ogungbenro, A Patel, R Duncombe, R Nuttall, J Clark, P Lorigan
Clinical Pharmacology & Therapeutics 103 (4), 582-590, 2018
622018
Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 the REMAP-CAP COVID-19 immune modulation therapy domain randomized clinical trial
REMAP-CAP Investigators, LPG Derde, AC Gordon, PR Mouncey, ...
MedRxiv, 2021.06. 18.21259133, 2021
592021
Pharmacokinetic modelling of interleukin‐1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid haemorrhage
I Gueorguieva, SR Clark, CJ McMahon, S Scarth, NJ Rothwell, PJ Tyrell, ...
British journal of clinical pharmacology 65 (3), 317-325, 2008
592008
Anakinra in COVID-19: important considerations for clinical trials
A King, A Vail, C O'Leary, C Hannan, D Brough, H Patel, J Galea, ...
The Lancet Rheumatology 2 (7), e379-e381, 2020
532020
The system can't perform the operation now. Try again later.
Articles 1–20